To Our Respected Customers and Investors,

Since its establishment in 2019, iPS Bio has been dedicated to overcoming intractable diseases through innovative stem cell therapies and the development of advanced drug screening platforms.

We focus on developing cell therapies using stem cells and establishing drug screening platforms using patient-derived iPSCs (induced pluripotent stem cells). As part of these efforts, we aim to provide new treatment options for intractable diseases and offer customized stem cell banking services to advance precision medicine. These initiatives reflect our core vision of driving patient-centered treatment innovation.

Our company provides stem cell-based solutions for treating intractable diseases such as Huntington’s disease and stroke, as well as specialized drug screening platforms for neurodegenerative diseases, including Alzheimer’s and Huntington’s diseases. Through these efforts, we continue to showcase our unique technologies in the global biopharmaceutical industry. These achievements are made possible by the dedication of our research team and the trust and collaboration of our customers and partners.

We remain committed to expanding the possibilities of healthcare through stem cell-based therapies and precision medicine services. Moving forward, we will continue our mission to overcome intractable diseases and make patient-centered precision medicine a reality.

Yours faithfully,